Citation: | Shen Ze, Tian Yangyang, Zhou Zheng, et al. Clinical and epidemiological features analysis of pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 570-577. doi: 10.3969/j.issn.1674-7445.2023.04.014 |
[1] |
HOSSEINI-MOGHADDAM SM, OUÉDRAOGO A, NAYLOR KL, et al. Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: a population-based cohort study[J]. Transpl Infect Dis, 2020, 22(2): e13250. DOI: 10.1111/tid.13250.
|
[2] |
APOSTOLOPOULOU A, FISHMAN JA. The pathogenesis and diagnosis of pneumocystis jiroveci pneumonia[J]. J Fungi (Basel), 2022, 8(11): 1167. DOI: 10.3390/jof8111167.
|
[3] |
HOSSEINI-MOGHADDAM SM, SHOKOOHI M, SINGH G, et al. Six-month risk of pneumocystis pneumonia following acute cellular rejection: a case-control study in solid organ transplant recipients[J]. Clin Transplant, 2021, 35(7): e14322. DOI: 10.1111/ctr.14322.
|
[4] |
ZHANG F, CHEN J, HUANG H, et al. Application of metagenomic next-generation sequencing in the diagnosis and treatment guidance of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(9): 1933-1942. DOI: 10.1007/s10096-021-04254-x.
|
[5] |
XIE D, XU W, YOU J, et al. Clinical descriptive analysis of severe pneumocystis jirovecii pneumonia in renal transplantation recipients[J]. Bioengineered, 2021, 12(1): 1264-1272. DOI: 10.1080/21655979.2021.1911203.
|
[6] |
XU J, YU Y, LV J, et al. Application of metagenomic next-generation sequencing to diagnose pneumocystis jirovecii pneumonia in kidney transplantation recipients[J]. Ann Transplant, 2021, 26: e931059. DOI: 10.12659/AOT.931059.
|
[7] |
DE BOER MG, DE FIJTER JW, KROON FP. Outbreaks and clustering of pneumocystis pneumonia in kidney transplant recipients: a systematic review[J]. Med Mycol, 2011, 49(7): 673-680. DOI: 10.3109/13693786.2011.571294.
|
[8] |
LE GAL S, TOUBAS D, TOTET A, et al. Pneumocystis infection outbreaks in organ transplantation units in France: a nation-wide survey[J]. Clin Infect Dis, 2020, 70(10): 2216-2220. DOI: 10.1093/cid/ciz901.
|
[9] |
RICCI G, SANTOS DW, KOVACS JA, et al. Genetic diversity of pneumocystis jirovecii from a cluster of cases of pneumonia in renal transplant patients: cross-sectional study[J]. Mycoses, 2018, 61(11): 845-852. DOI: 10.1111/myc.12823.
|
[10] |
MAITTE C, LETERRIER M, LE PAPE P, et al. Multilocus sequence typing of pneumocystis jirovecii from clinical samples: how many and which loci should be used?[J]. J Clin Microbiol, 2013, 51(9): 2843-2849. DOI: 10.1128/JCM.01073-13.
|
[11] |
韩嘉静, 赵建康, 刘鑫梦, 等. 耶氏肺孢子菌肺炎临床特征分析[J]. 中华检验医学杂志, 2022, 45(9): 930-935. DOI: 10.3760/cma.j.cn114452-20211108-00689.
HAN JJ, LIU JK, LIU XM, et al. Clinical features of pneumocystis jirovecii pneumonia[J]. Chin J Lab Med, 2022, 45(9): 930-935. DOI: 10.3760/cma.j.cn114452-20211108-00689.
|
[12] |
薛婷, 杜伟勤. 耶氏肺孢子菌基因分型研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 842-847. DOI: 10.12140/j.issn.1000-7423.2021.06.018.
XUE T, DU WQ. Progress in genotyping of pneumocystis jirovecii[J]. Chin J Parasitol Parasit Dis, 2021, 39(6): 842-847. DOI: 10.12140/j.issn.1000-7423.2021.06.018.
|
[13] |
孟静, 李光才, 肖建生, 等. 不同免疫状态下卡氏肺孢子菌肺炎临床特征的差异性分析[J]. 华中科技大学学报(医学版), 2021, 50(2): 225-229. DOI: 10.3870/j.issn.1672-0741.2021.02.016.
MENG J, LI GC, XIAO JS, et al. Difference analysis of the clinical features of pneumocystis carinii pneumonia under different immune status[J]. Acta Med Univ Sci Technol Huazhong, 2021, 50(2): 225-229. DOI: 10.3870/j.issn.1672-0741.2021.02.016.
|
[14] |
王明明, 杨学敏. 肾移植术后患者肺孢子菌肺炎临床特征分析[J]. 临床肺科杂志, 2020, 25(9): 1355-1358. DOI: 10.3969/j.issn.1009-6663.2020.09.014.
WANG MM, YANG XM. Clinical characteristics of pneumocystis pneumonia in patients after renal transplantation[J]. J Clin Pulm Med, 2020, 25(9): 1355-1358. DOI: 10.3969/j.issn.1009-6663.2020.09.014.
|
[15] |
TASAKA S. Recent advances in the diagnosis and management of pneumocystis pneumonia[J]. Tuberc Respir Dis (Seoul), 2020, 83(2): 132-140. DOI: 10.4046/trd.2020.0015.
|
[16] |
HAMMARSTRÖM H, GRANKVIST A, BROMAN I, et al. Serum-based diagnosis of pneumocystis pneumonia by detection of pneumocystis jirovecii DNA and 1, 3-β-D-glucan in HIV-infected patients: a retrospective case control study[J]. BMC Infect Dis, 2019, 19(1): 658. DOI: 10.1186/s12879-019-4289-4.
|
[17] |
GUEGAN H, ROBERT-GANGNEUX F. Molecular diagnosis of pneumocystis pneumonia in immunocompromised patients[J]. Curr Opin Infect Dis, 2019, 32(4): 314-321. DOI: 10.1097/QCO.0000000000000559.
|
[18] |
ZHAN Y, GAO X, LI S, et al. Development and evaluation of rapid and accurate CRISPR/Cas13-based RNA diagnostics for pneumocystis jirovecii pneumonia[J]. Front Cell Infect Microbiol, 2022, 12: 904485. DOI: 10.3389/fcimb.2022.904485.
|
[19] |
WANG J, HAN Y, FENG J. Metagenomic next-generation sequencing for mixed pulmonary infection diagnosis[J]. BMC Pulm Med, 2019, 19(1): 252. DOI: 10.1186/s12890-019-1022-4.
|
[20] |
LU X, ZHANG J, MA W, et al. Pneumocystis jirovecii pneumonia diagnosis via metagenomic next-generation sequencing[J]. Front Med (Lausanne), 2022, 9: 812005. DOI: 10.3389/fmed.2022.812005.
|
[21] |
冯玲, 熊佳丽, 易荣, 等. 宏基因组二代测序在肺部感染诊治的临床价值[J]. 临床肺科杂志, 2021, 26(12): 1834-1838. DOI: 10.3969/j.issn.1009-6663.2021.12.011.
FENG L, XIONG JL, YI R, et al. Clinical value of metagenomic next-generation sequencing in diagnosis and treatment of pulmonary infection[J]. J Clin Pulm Med, 2021, 26(12): 1834-1838. DOI: 10.3969/j.issn.1009-6663.2021.12.011.
|
[22] |
沈轶, 潘雁, 尹成胜, 等. 二代测序诊断肺移植后耶氏肺孢子菌肺炎二例并文献复习[J]. 中国呼吸与危重监护杂志, 2021, 20(7): 479-486. DOI: 10.7507/1671-6205.202104007.
SHEN Y, PAN Y, YIN CS, et al. Pneumocystis jirovecii pneumonia diagnosed by next-genetation sequencing after lung transplantation: case report and literature review[J]. Chin J Respir Crit Care Med, 2021, 20(7): 479-486. DOI: 10.7507/1671-6205.202104007.
|
[23] |
张彩霞, 刘新年, 杜川, 等. mNGS技术和血清G试验在判断耶氏肺孢子菌感染与定植中的价值及二者相关性研究[J]. 中国全科医学, 2023, 26(11): 1355-1360. DOI: 10.12114/j.issn.1007-9572.2022.0594.
ZHANG CX, LIU XN, DU C, et al. mNGS and serum G test in distinguishing between pneumocystis jirovecii colonization and infection: value comparison and correlation analysis[J]. Chin Gen Pract, 2023, 26(11): 1355-1360. DOI: 10.12114/j.issn.1007-9572.2022.0594.
|
[24] |
LIU L, YUAN M, SHI Y, et al. Clinical performance of BAL metagenomic next-generation sequence and serum (1, 3)-β-D-glucan for differential diagnosis of pneumocystis jirovecii pneumonia and pneumocystis jirovecii colonization[J]. Front Cell Infect Microbiol, 2021, 11: 784236. DOI: 10.3389/fcimb.2021.784236.
|
[25] |
BATEMAN M, OLADELE R, KOLLS JK. Diagnosing pneumocystis jirovecii pneumonia: a review of current methods and novel approaches[J]. Med Mycol, 2020, 58(8): 1015-1028. DOI: 10.1093/mmy/myaa024.
|
[26] |
LEE G, KOO TY, KIM HW, et al. Comparison of early and late pneumocystis jirovecii pneumonia in kidney transplant patients: the Korean Organ Transplantation Registry (KOTRY) study[J]. Sci Rep, 2022, 12(1): 10682. DOI: 10.1038/s41598-022-14580-5.
|
[27] |
KUMAR D, GOURISHANKAR S, MUELLER T, et al. pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient[J]. Transpl Infect Dis, 2009, 11(2): 167-170. DOI: 10.1111/j.1399-3062.2008.00345.x.
|
[28] |
PERRIER Q, PORTAIS A, TERREC F, et al. A case of pneumocystis jirovecii pneumonia under belatacept and everolimus: benefit-risk balance between renal allograft function and infection[J]. Case Rep Nephrol Dial, 2021, 11(1): 10-15. DOI: 10.1159/000510842.
|
[29] |
AZAR MM, COHEN E, MA L, et al. Genetic and epidemiologic analyses of an outbreak of pneumocystis jirovecii pneumonia among kidney transplant recipients in the United States[J]. Clin Infect Dis, 2022, 74(4): 639-647. DOI: 10.1093/cid/ciab474.
|
[30] |
KAMINSKI H, BELLIERE J, BURGUET L, et al. Identification of predictive markers and outcomes of late-onset pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. Clin Infect Dis, 2021, 73(7): e1456-e1463. DOI: 10.1093/cid/ciaa1611.
|
[31] |
ZOU J, QIU T, ZHOU J, et al. Clinical manifestations and outcomes of renal transplantation patients with pneumocystis jirovecii pneumonia and cytomegalovirus co-infection[J]. Front Med (Lausanne), 2022, 9: 860644. DOI: 10.3389/fmed.2022.860644.
|
[32] |
LEE S, PARK Y, KIM SG, et al. The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with pneumocystis jirovecii pneumonia[J]. Microbiol Immunol, 2020, 64(5): 356-365. DOI: 10.1111/1348-0421.12778.
|
[33] |
DUAN J, GAO J, LIU Q, et al. Characteristics and prognostic factors of non-HIV immunocompromised patients with pneumocystis pneumonia diagnosed by metagenomics next-generation sequencing[J]. Front Med (Lausanne), 2022, 9: 812698. DOI: 10.3389/fmed.2022.812698.
|
[34] |
MEYER AMJ, SIDLER D, HIRZEL C, et al. Distinct clinical and laboratory patterns of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. J Fungi (Basel), 2021, 7(12): 1072. DOI: 10.3390/jof7121072.
|
[35] |
LING J, ANDERSON T, WARREN S, et al. Hypercalcaemia preceding diagnosis of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Clin Kidney J, 2017, 10(6): 845-851. DOI: 10.1093/ckj/sfx044.
|
[36] |
MARTIN SI, FISHMAN JA, AST Infectious Diseases Community of Practice. pneumocystis pneumonia in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 272-279. DOI: 10.1111/ajt.12119.
|
[37] |
段艳, 徐媛, 杨长青, 等. 复方磺胺甲
DUAN Y, XU Y, YANG CQ, et al. Meta-analysis of trimethoprim-sulfamethoxazole combined with caspofungin in the treatment of pneumocys-tis jirovecii pneumonia[J]. Chin J Mycol, 2023, 18(1): 1-7. DOI: 10.3969/j.issn.1673-3827.2023.01.001.
|
[38] |
姚芳, 路敏, 孔妍, 等. 耶氏肺孢子虫肺炎患者复方磺胺甲
YAO F, LU M, KONG Y, et al. Analysis of the dose adjustment of compound sulfamethoxazole in a patient with pneumocystis pneumonia[J]. Chin J Clin Pharm, 2022, 38(3): 267-269. DOI: 10.13699/j.cnki.1001-6821.2022.03.017.
|
[39] |
TU GW, JU MJ, XU M, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Nephrology (Carlton), 2013, 18(11): 736-742. DOI: 10.1111/nep.12133.PMID:24571744.
|
[40] |
JI J, WANG Q, HUANG T, et al. Efficacy of low-dose trimethoprim/sulfamethoxazole for the treatment of pneumocystis jirovecii pneumonia in deceased donor kidney recipients[J]. Infect Drug Resist, 2021, 14: 4913-4920. DOI: 10.2147/IDR.S339622.
|
[41] |
GU ZY, LIU WJ, HUANG DL, et al. Preliminary study on the combination effect of clindamycin and low dose trimethoprim-sulfamethoxazole on severe pneumocystis pneumonia after renal transplantation[J]. Front Med (Lausanne), 2022, 9: 827850. DOI: 10.3389/fmed.2022.827850.
|